RJFSA
SNDX icon

Raymond James Financial Services Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-34,597
Closed -$880K – 3393
2022
Q4 		$880K Buy
+34,597
New +$807K ﹤0.01% 1922

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Raymond James Financial Services Advisors's SNDX Position: Q1 2023 in Review

Raymond James Financial Services Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 34,597 shares — an estimated $880K sold.

Raymond James Financial Services Advisors first reported a position in SNDX in Q4 2022 and held it in 1 quarter. The position peaked at $880K in Q4 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • Raymond James Financial Services Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 34,597 Syndax Pharmaceuticals shares in Q1 2023, an estimated $880K.
  • Raymond James Financial Services Advisors first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Syndax Pharmaceuticals position peaked at $880K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.